Best for
Mobile

Posted
AgeX Therapeutics, Inc (AGE) is a leading biotechnology business based in the US. It opened the day at $2.2 after a previous close of $2.23. During the day the price has varied from a low of $2.08 to a high of $2.2369. The latest price was $2.08 (25 minute delay). AgeX Therapeutics is listed on the NYSE MKT and employs 17 staff. All prices are listed in US Dollars.
Open | $2.2 |
---|---|
High | $2.2369 |
Low | $2.08 |
Close | $2.08 |
Previous close | $2.23 |
Change | $-0.15 |
Change % | -6.7265% |
Volume | 239,836 |
52-week range | $0.666 - $3.06 |
---|---|
50-day moving average | $2.1003 |
200-day moving average | $1.577 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.318 |
Other fees may apply. Your capital is at risk.
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
---|---|---|---|---|
![]() |
£0 | No minimum | £4.39 £154.94 total |
Capital at risk |
![]() |
£0 | $500 | £0.75 £151.30 total |
Capital at risk |
![]() |
£0 | £0.01 | £0.87 £151.42 total |
Capital at risk |
![]() |
£0 | £50 | £1.04 £151.59 total |
Capital at risk |
![]() |
£0 | £1 | £13.75 £164.30 total |
Capital at risk |
![]() |
£9.99 per month | No minimum | £10.54 £161.09 total |
Capital at risk |
![]() |
£0 | £20 | £14.67 £165.22 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $2.08
1 week (2021-02-25) | -0.72% |
---|---|
1 month (2021-02-05) | -0.95% |
3 months (2020-12-04) | 22.35% |
6 months (2020-09-04) | 160.33% |
1 year (2020-03-04) | 84.07% |
---|---|
2 years (2019-03-04) | -49.88% |
Revenue TTM | $1.9 million |
---|---|
Gross profit TTM | $1.5 million |
Return on assets TTM | -110.41% |
Return on equity TTM | -1881.2% |
Profit margin | 0% |
Book value | $0.115 |
Market capitalisation | $95 million |
TTM: trailing 12 months
There are currently 407,255 AgeX Therapeutics shares held short by investors – that's known as AgeX Therapeutics's "short interest". This figure is 12% up from 363,471 last month.
There are a few different ways that this level of interest in shorting AgeX Therapeutics shares can be evaluated.
AgeX Therapeutics's "short interest ratio" (SIR) is the quantity of AgeX Therapeutics shares currently shorted divided by the average quantity of AgeX Therapeutics shares traded daily (recently around 490668.6746988). AgeX Therapeutics's SIR currently stands at 0.83. In other words for every 100,000 AgeX Therapeutics shares traded daily on the market, roughly 830 shares are currently held short.
However AgeX Therapeutics's short interest can also be evaluated against the total number of AgeX Therapeutics shares, or, against the total number of tradable AgeX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AgeX Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 AgeX Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0192% of the tradable shares (for every 100,000 tradable AgeX Therapeutics shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AgeX Therapeutics.
Find out more about how you can short AgeX Therapeutics stock.
We're not expecting AgeX Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
AgeX Therapeutics's shares were split on a 15:16 basis on 6 May 2015. So if you had owned 16 shares the day before before the split, the next day you'd have owned 15 shares. This wouldn't directly have changed the overall worth of your AgeX Therapeutics shares – just the quantity. However, indirectly, the new 6.7% higher share price could have impacted the market appetite for AgeX Therapeutics shares which in turn could have impacted AgeX Therapeutics's share price.
Over the last 12 months, AgeX Therapeutics's shares have ranged in value from as little as $0.666 up to $3.06. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while AgeX Therapeutics's is 1.4498. This would suggest that AgeX Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Subscribe to trending stock alerts for a chance to win
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.
Learn more about Vroom’s recent performance and where you can invest in Vroom shares. We also run through some helpful rules of thumb for any investor.
Learn more about Washington Prime Group’s recent performance and where you can invest in Washington Prime shares. We also run through some helpful rules of thumb for any investor.
Learn more about Vertu Capital’s recent performance and where you can invest in Vertu Capital shares. We also run through some helpful rules of thumb for any investor.
Learn more about ReTo Eco-Solutions’ recent performance and where you can invest in ReTo Eco-Solutions shares. We also run through some helpful rules of thumb for any investor.
Ever wondered how to buy shares in RCI Hospitality Holdings? We explain how and compare a range of providers that can give you access to many brands, including RCI Hospitality Holdings.
Ever wondered how to buy shares in Norfolk Southern? We explain how and compare a range of providers that can give you access to many brands, including Norfolk Southern.
Ever wondered how to buy shares in ResMed? We explain how and compare a range of providers that can give you access to many brands, including ResMed.
Ever wondered how to buy shares in Motorola Solutions? We explain how and compare a range of providers that can give you access to many brands, including Motorola Solutions.
Ever wondered how to buy shares in Kinder Morgan? We explain how and compare a range of providers that can give you access to many brands, including Kinder Morgan.
Ever wondered how to buy shares in Enterprise Products Partners? We explain how and compare a range of providers that can give you access to many brands, including Enterprise Products Partners.